WEBULL
News
SILO
0.4388
-2.81%
-0.0127
Weekly Report: what happened at SILO last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at SILO last week (1117-1121)?
Weekly Report · 11/24 09:45
Silo Pharma CEO Eric Weisblum Acquires Common Shares
Reuters · 11/21 23:36
Silo Pharma CEO Eric Weisblum Reports Acquisition of Common Shares
Reuters · 11/20 21:01
Psychedelic: Clearmind reports results from first cohort in AUD trial
TipRanks · 11/20 17:05
Silo Pharma Partners with Allucent to Advance PTSD Drug Toward Clinical Trials
Reuters · 11/17 13:25
Silo Pharma partners with Allucent for planned FDA IND application for SPC-15
TipRanks · 11/17 13:11
SILO PHARMA INC - DATA FROM GLP-COMPLIANT TOXICOLOGY STUDY EXPECTED IN EARLY 2026
Reuters · 11/17 13:05
Weekly Report: what happened at SILO last week (1110-1114)?
Weekly Report · 11/17 09:45
Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
Barchart · 11/17 07:05
Weekly Report: what happened at SILO last week (1103-1107)?
Weekly Report · 11/10 09:43
Weekly Report: what happened at SILO last week (1027-1031)?
Weekly Report · 11/03 09:43
Silo Pharma selects AlphaLedger’s T12 Fund for tokenized RWA investments
TipRanks · 10/29 12:30
Silo Pharma Selects The Alphaledger/Simplify Target 12% Distribution Fund As Part Of Its Real-World Asset Investment Strategy On The Solana Blockchain
Benzinga · 10/29 12:27
SILO PHARMA SELECTS ALPHALEDGER’S T12 FUND FOR TOKENIZED REAL-WORLD ASSET INVESTMENTS ON SOLANA BLOCKCHAIN
Reuters · 10/29 12:25
Weekly Report: what happened at SILO last week (1020-1024)?
Weekly Report · 10/27 09:45
Silo Pharma Shareholders Approve Key Proposals at Annual Meeting
TipRanks · 10/24 20:57
Psychedelic: Clearmind enrolls last patient in first cohort of CMND-100 trial
TipRanks · 10/23 15:20
More
Webull provides a variety of real-time SILO stock news. You can receive the latest news about Silo Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About SILO
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.